has entered into a partnership with BioSimilar Sciences PR LLC (BSS), US, to focus on a next-generation monoclonal antibody biosimilar targeting cancer and autoimmune diseases. Ipca will transfer late-stage development, clinical manufacturing, and commercial supply to BSS’ 200,000 sq. ft facility in Puerto Rico.
has received tentative approval from the US health regulator for the generic version of Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets used to treat the human immunodeficiency virus (HIV) infection.
Glenmark Specialty SA, subsidiary of has signed an exclusive licence and collaboration pact with Hengrui Pharma for development and commercialisation of Trastuzumab Rezetecan, that is aimed at treating different types of cancer. Under the agreement, Glenmark obtains exclusive rights to develop and commercialise Trastuzumab Rezetecan worldwide, excluding Mainland China, the Hong Kong SAR, the Macao SAR, Taiwan Region, US, Canada, Europe, Japan, Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan and Uzbekistan, it added. Glenmark will pay an upfront payment of $18 million. Hengrui is eligible to receive regulatory and commercial milestone payments of up to $1.093 billion.
has signed an agreement to acquire Medistream SA, including Citieffe SRL and its subsidiaries in the US and Mexico. The deal is valued at ₹324 crore.